Activin and Inhibin

Bevenopran is a peripheral μ-opioid receptor antagonistIn VivoBevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD) . Bevenopran tends to

Bevenopran is a peripheral μ-opioid receptor antagonistIn VivoBevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD) . Bevenopran tends to

BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP 4 receptor antagonist, with a pK B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headacheIn VitroBGC-20-1531 free base competitively antagonized

BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP 4 receptor antagonist, with a pK B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headacheIn VitroBGC-20-1531 free base competitively antagonized

BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP 4 receptor antagonist, with a pK B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headacheIn VitroBGC-20-1531 free base competitively antagonized

BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP 4 receptor antagonist, with a pK B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headacheIn VitroBGC-20-1531 free base competitively antagonized

BGG463 (K03859) is an orally active type II CDK2 inhibitorIn VitroBGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML. MCE has not independently confirmed the accuracy of these methods. They

BGG463 (K03859) is an orally active type II CDK2 inhibitorIn VitroBGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML. MCE has not independently confirmed the accuracy of these methods. They

BGG463 (K03859) is an orally active type II CDK2 inhibitorIn VitroBGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML. MCE has not independently confirmed the accuracy of these methods. They

BGG463 (K03859) is an orally active type II CDK2 inhibitorIn VitroBGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML. MCE has not independently confirmed the accuracy of these methods. They

BGG463 (K03859) is an orally active type II CDK2 inhibitorIn VitroBGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML. MCE has not independently confirmed the accuracy of these methods. They

BGG463 (K03859) is an orally active type II CDK2 inhibitorIn VitroBGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML. MCE has not independently confirmed the accuracy of these methods. They